Dusko Ilic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7969449/publications.pdf

Version: 2024-02-01

208 papers	12,086 citations	47 h-index	108 g-index
		47006	25787
214 all docs	214 docs citations	214 times ranked	12930 citing authors

#	Article	IF	Citations
1	Industry updates from the field of stem cell research and regenerative medicine in October 2021. Regenerative Medicine, 2022, 17, 55-62.	1.7	1
2	Industry updates from the field of stem cell research and regenerative medicine in November 2021. Regenerative Medicine, 2022, 17, 107-117.	1.7	0
3	Epidermal Basement Membrane Substitutes for Bioengineering of Human Epidermal Equivalents. JID Innovations, 2022, 2, 100083.	2.4	4
4	Industry updates from the field of stem cell research and regenerative medicine in February 2022. Regenerative Medicine, 2022, , .	1.7	2
5	Industry updates from the field of stem cell research and regenerative medicine in January 2022. Regenerative Medicine, 2022, , .	1.7	1
6	Industry updates from the field of stem cell research and regenerative medicine in December 2021. Regenerative Medicine, 2022, 17, 185-191.	1.7	0
7	Industry updates from the field of stem cell research and regenerative medicine in March 2022. Regenerative Medicine, 2022, , .	1.7	0
8	Pluripotent Stem Cells in Clinical Settingâ€"New Developments and Overview of Current Status. Stem Cells, 2022, 40, 791-801.	3.2	8
9	Industry updates from the field of stem cell research and regenerative medicine in April 2022. Regenerative Medicine, 2022, 17, 507-515.	1.7	0
10	Industry updates from the field of stem cell research and regenerative medicine in September 2020. Regenerative Medicine, 2021, 16, 1-8.	1.7	1
11	Perspective and Consensus Opinion: Good Practices for Using Organotypic Skin and Epidermal Equivalents in Experimental Dermatology Research. Journal of Investigative Dermatology, 2021, 141, 203-205.	0.7	13
12	Industry updates from the field of stem cell research and regenerative medicine in October 2020. Regenerative Medicine, 2021, 16, 101-111.	1.7	0
13	Industry updates from the field of stem cell research and regenerative medicine in November 2020. Regenerative Medicine, 2021, 16, 323-329.	1.7	2
14	Industry updates from the field of stem cell research and regenerative medicine in December 2020. Regenerative Medicine, 2021, 16, 331-341.	1.7	1
15	Industry updates from the field of stem cell research and regenerative medicine in January 2021. Regenerative Medicine, 2021, 16, 423-429.	1.7	2
16	Human pluripotent stem cells: An alternative for 3D in vitro modelling of skin disease. Experimental Dermatology, 2021, 30, 1572-1587.	2.9	6
17	Industry updates from the field of stem cell research and regenerative medicine in February 2021. Regenerative Medicine, 2021, 16, 517-523.	1.7	1
18	Industry updates from the field of stem cell research and regenerative medicine in March 2021. Regenerative Medicine, 2021, 16, 607-613.	1.7	0

#	Article	IF	Citations
19	Industry updates from the field of stem cell research and regenerative medicine in June 2021. Regenerative Medicine, 2021, 16, 893-903.	1.7	0
20	Induced pluripotent stem cell (iPSC) line MLi-004A derived from a patient with recessive dystrophic epidermolysis bullosa (RDEB). Stem Cell Research, 2021, 55, 102463.	0.7	0
21	Industry updates from the field of stem cell research and regenerative medicine in April 2021. Regenerative Medicine, 2021, 16, 703-707.	1.7	0
22	Industry updates from the field of stem cell research and regenerative medicine in May 2021. Regenerative Medicine, 2021, 16, 814-821.	1.7	0
23	Industry updates from the field of stem cell research and regenerative medicine in July 2021. Regenerative Medicine, 2021, 16, 963-969.	1.7	0
24	Industry updates from the field of stem cell research and regenerative medicine in August 2021. Regenerative Medicine, 2021, 16, 1021-1028.	1.7	0
25	Industry updates from the field of stem cell research and regenerative medicine in September 2021. Regenerative Medicine, 2021, , .	1.7	0
26	Effects of thyroid hormone on mitochondria and metabolism of human preimplantation embryos. Stem Cells, 2020, 38, 369-381.	3.2	20
27	Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. Journal of the American Academy of Dermatology, 2020, 83, 447-454.	1.2	50
28	Industry updates from the field of stem cell research and regenerative medicine in September 2019. Regenerative Medicine, 2020, 15, 1161-1170.	1.7	0
29	Markers for Ca ++ â€induced terminal differentiation of keratinocytes in vitro under defined conditions. Experimental Dermatology, 2020, 29, 1238-1242.	2.9	2
30	Industry updates from the field of stem cell research and regenerative medicine in June 2020. Regenerative Medicine, 2020, 15, 2145-2152.	1.7	1
31	Industry updates from the field of stem cell research and regenerative medicine in July 2020. Regenerative Medicine, 2020, 15, 2253-2260.	1.7	1
32	Industry updates from the field of stem cell research and regenerative medicine in August 2020. Regenerative Medicine, 2020, 15, 2329-2334.	1.7	1
33	Stem Cell Research Lab Resource: Stem Cell LineInduced pluripotent stem cell (iPSC) line MLi-003A derived from an individual with the maximum number of filaggrin (FLG) tandem repeats. Stem Cell Research, 2020, 45, 101827.	0.7	3
34	Industry updates from the field of stem cell research and regenerative medicine in February 2020. Regenerative Medicine, 2020, 15, 1689-1694.	1.7	0
35	mRNA-Based Reprogramming Under Xeno-Free and Feeder-Free Conditions. Methods in Molecular Biology, 2020, , 1.	0.9	1
36	Industry updates from the field of stem cell research and regenerative medicine in October 2019. Regenerative Medicine, 2020, 15, 1251-1259.	1.7	1

#	Article	IF	Citations
37	Industry updates from the field of stem cell research and regenerative medicine in January 2020: Industry News. Regenerative Medicine, 2020, 15, 1595-1601.	1.7	2
38	Industry updates from the field of stem cell research and regenerative medicine in March 2020. Regenerative Medicine, 2020, 15, 1833-1840.	1.7	1
39	Industry updates from the field of stem cell research and regenerative medicine in December 2019. Regenerative Medicine, 2020, 15, 1499-1507.	1.7	1
40	Industry updates from the field of stem cell research and regenerative medicine in November 2019. Regenerative Medicine, 2020, 15, 1371-1379.	1.7	0
41	Industry updates from the field of stem cell research and regenerative medicine in May 2020. Regenerative Medicine, 2020, 15, 2045-2051.	1.7	0
42	Industry updates from the field of stem cell research and regenerative medicine in April 2020. Regenerative Medicine, 2020, 15, 1943-1950.	1.7	0
43	Definition and validation of a custom protocol to detect miRNAs in the spent media after blastocyst culture: searching for biomarkers of implantation. Human Reproduction, 2019, 34, 1746-1761.	0.9	21
44	Induced pluripotent stem cell line heterozygous for p.R501X mutation in filaggrin: KCLi003-A. Stem Cell Research, 2019, 39, 101527.	0.7	5
45	Industry updates from the field of stem cell research and regenerative medicine in August 2019. Regenerative Medicine, 2019, 14, 1071-1075.	1.7	0
46	Industry updates from the field of stem cell research and regenerative medicine in July 2019. Regenerative Medicine, 2019, 14, 991-996.	1.7	0
47	Industry updates from the field of stem cell research and regenerative medicine in June 2019. Regenerative Medicine, 2019, 14, 905-913.	1.7	0
48	Industry updates from the field of stem cell research and regenerative medicine in May 2019. Regenerative Medicine, 2019, 14, 815-822.	1.7	0
49	Industry updates from the field of stem cell research and regenerative medicine in April 2019. Regenerative Medicine, 2019, 14, 721-733.	1.7	0
50	What can stem cell technology offer to <scp>IVF</scp> patients?. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 824-827.	2.3	3
51	Comparison of human isogeneic Whartonâ€™s jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulation. Cell Death and Disease, 2019, 10, 277.	6.3	12
52	Induced pluripotent stem cell line heterozygous for p.R2447X mutation in filaggrin: KCLi002-A. Stem Cell Research, 2019, 38, 101462.	0.7	3
53	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in November 2018. Regenerative Medicine, 2019, 14, 139-144.	1.7	0
54	Induced pluripotent stem cell (iPSC) line from an epidermolysis bullosa simplex patient heterozygous for keratin 5 E475G mutation and with the Dowling Meara phenotype. Stem Cell Research, 2019, 37, 101424.	0.7	6

#	Article	IF	Citations
55	Industry updates from the field of stem cell research and regenerative medicine in January 2019. Regenerative Medicine, 2019, 14, 345-351.	1.7	0
56	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions September 1â€“30, 2018. Regenerative Medicine, 2019, 14, 7-13.	1.7	0
57	Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy. Stem Cells Translational Medicine, 2019, 8, 124-137.	3.3	40
58	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in October 2018. Regenerative Medicine, 2019, 14, 85-92.	1.7	0
59	Prospects for the Use of Induced Pluripotent Stem Cells in Animal Conservation and Environmental Protection. Stem Cells Translational Medicine, 2019, 8, 7-13.	3.3	45
60	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 Septemberâ€“30ÂSeptemberÂ2017. Regenerative Medicine, 2018, 13, 13-18.	1.7	0
61	Segregation of mitochondrial DNA heteroplasmy through a developmental genetic bottleneck in human embryos. Nature Cell Biology, 2018, 20, 144-151.	10.3	182
62	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutionsÂ1 November â€“ 31 December 2017. Regenerative Medicine, 2018, 13, 269-276.	1.7	0
63	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions 1 Julyâ€“31 August 2018. Regenerative Medicine, 2018, 13, 875-880.	1.7	0
64	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 Aprilâ€“31 May 2018. Regenerative Medicine, 2018, 13, 633-641.	1.7	0
65	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions June 1â€“June 30, 2018. Regenerative Medicine, 2018, 13, 867-874.	1.7	0
66	Induced pluripotent stem cell line from an atopic dermatitis patient heterozygous for c.2282del4 mutation in filaggrin: KCLi001-A. Stem Cell Research, 2018, 31, 122-126.	0.7	5
67	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€“31 March 2018. Regenerative Medicine, 2018, 13, 497-501.	1.7	0
68	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 January â€“28 February 28 2018. Regenerative Medicine, 2018, 13, 361-370.	1.7	2
69	Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature, 2017, 545, 229-233.	27.8	409
70	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions, 1 Januaryâ€“28 February 2017. Regenerative Medicine, 2017, 12, 321-330.	1.7	2
71	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 Aprilâ€“31 May 2017. Regenerative Medicine, 2017, 12, 721-731.	1.7	1
72	Human embryos from induced pluripotent stem cell-derived gametes: ethical and quality considerations. Regenerative Medicine, 2017, 12, 681-691.	1.7	6

#	Article	IF	Citations
73	Effects of maternal obesity on Whartonâ€™s Jelly mesenchymal stromal cells. Scientific Reports, 2017, 7, 17595.	3.3	8
74	Pluripotent state transitions coordinate morphogenesis in mouse and human embryos. Nature, 2017, 552, 239-243.	27.8	193
75	Concise Review: Human Embryonic Stem Cellsâ€"What Have We Done? What Are We Doing? Where Are We Going?. Stem Cells, 2017, 35, 17-25.	3.2	137
76	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutionsÂ1 Julyâ€"31 August 2017. Regenerative Medicine, 2017, 12, 905-916.	1.7	1
77	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€"30 June, 2017. Regenerative Medicine, 2017, 12, 887-892.	1.7	0
78	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions 1 Januaryâ€"29 February 2016. Regenerative Medicine, 2016, 11, 363-371.	1.7	0
79	iPSC in the past decade: the Japanese dominance. Regenerative Medicine, 2016, 11, 747-749.	1.7	8
80	Self-Organization of the Human Embryo in the Absence of Maternal Tissues. Obstetrical and Gynecological Survey, 2016, 71, 718-719.	0.4	0
81	Generation of KCL035 research grade human embryonic stem cell line carrying a mutation in HBB gene. Stem Cell Research, 2016, 16, 210-212.	0.7	3
82	Generation of KCL033 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 296-299.	0.7	1
83	Generation of KCL018 research grade human embryonic stem cell line carrying a mutation in the DMPK gene. Stem Cell Research, 2016, 16, 342-344.	0.7	2
84	Generation of KCL026 research grade human embryonic stem cell line carrying a mutation in SMN1 gene. Stem Cell Research, 2016, 16, 249-251.	0.7	0
85	Generation of KCL038 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 137-139.	0.7	3
86	Generation of KCL013 research grade human embryonic stem cell line carrying a mutation in the HTT gene. Stem Cell Research, 2016, 16, 293-295.	0.7	0
87	Generation of KCL021 research grade human embryonic stem cell line carrying a Î”F508 mutation in the CFTR gene. Stem Cell Research, 2016, 16, 177-179.	0.7	0
88	Generation of KCL028 research grade human embryonic stem cell line carrying a mutation in the HTT gene. Stem Cell Research, 2016, 16, 278-281.	0.7	0
89	Generation of KCL025 research grade human embryonic stem cell line carrying a mutation in NF1 gene. Stem Cell Research, 2016, 16, 256-258.	0.7	1
90	Generation of KCL024 research grade human embryonic stem cell line carrying a mutation in NF1 gene. Stem Cell Research, 2016, 16, 243-245.	0.7	0

#	Article	IF	Citations
91	Self-organization of the human embryo in the absence of maternal tissues. Nature Cell Biology, 2016, 18, 700-708.	10.3	516
92	Human Embryos Created by Embryo Splitting Secrete Significantly Lower Levels of miRNA-30c. Stem Cells and Development, 2016, 25, 1853-1862.	2.1	16
93	Generation of KCL039 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 170-172.	0.7	1
94	Generation of KCL036 research grade human embryonic stem cell line carrying a mutation in the HTT gene. Stem Cell Research, 2016, 16, 345-348.	0.7	0
95	Induced Pluripotent Stem Cell Differentiation and Three-Dimensional Tissue Formation Attenuate Clonal Epigenetic Differences in Trichohyalin. Stem Cells and Development, 2016, 25, 1366-1375.	2.1	10
96	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 April 2016â€“ 31 May 2016. Regenerative Medicine, 2016, 11, 499-505.	1.7	1
97	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€“31 March 2016. Regenerative Medicine, 2016, 11, 431-435.	1.7	0
98	Potential of human twin embryos generated by embryo splitting in assisted reproduction and research. Human Reproduction Update, 2016, 23, 156-165.	10.8	10
99	Generation of KCL017 research grade human embryonic stem cell line carrying a mutation in VHL gene. Stem Cell Research, 2016, 16, 268-270.	0.7	0
100	Generation of KCL031 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 195-198.	0.7	1
101	Generation of KCL029 research grade human embryonic stem cell line carrying a mutation in WAS gene. Stem Cell Research, 2016, 16, 189-191.	0.7	0
102	Generation of KCL032 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 17-19.	0.7	1
103	Generation of KCL027 research grade human embryonic stem cell line carrying a mutation in the HTT gene. Stem Cell Research, 2016, 16, 274-277.	0.7	0
104	Generation of KCL012 research grade human embryonic stem cell line carrying a mutation in the HTT gene. Stem Cell Research, 2016, 16, 264-267.	0.7	0
105	Generation of KCL016 research grade human embryonic stem cell line carrying a mutation in VHL gene. Stem Cell Research, 2016, 16, 37-39.	0.7	0
106	Generation of KCL034 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 184-188.	0.7	4
107	Generation of KCL040 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 173-176.	0.7	3
108	Human amniotic membrane grafts in therapy of chronic non-healing wounds: TableÂ1. British Medical Bulletin, 2016, 117, 59-67.	6.9	44

#	Article	IF	Citations
109	Generation of KCL037 clinical grade human embryonic stem cell line. Stem Cell Research, 2016, 16, 149-151.	0.7	2
110	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€“31 December 2015. Regenerative Medicine, 2016, 11, 235-240.	1.7	0
111	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 Augustâ€“30 September 2015. Regenerative Medicine, 2016, 11, 11-17.	1.7	2
112	MicroRNAs in spent blastocyst culture medium are derived fromÂtrophectoderm cells and canÂbeÂexplored for human embryoÂreproductive competence assessment. Fertility and Sterility, 2016, 105, 225-235.e3.	1.0	129
113	The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines. Scientific Reports, 2015, 5, 17258.	3.3	54
114	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€“30 June 2015. Regenerative Medicine, 2015, 10, 805-810.	1.7	0
115	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1â€“31 July 2015. Regenerative Medicine, 2015, 10, 931-934.	1.7	0
116	Three Huntingtonâ€™s Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. PLoS ONE, 2015, 10, e0126860.	2.5	17
117	Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1 Aprilâ€“31 May 2015. Regenerative Medicine, 2015, 10, 687-693.	1.7	0
118	Discordant Growth of Monozygotic Twins Starts at the Blastocyst Stage: A Case Study. Stem Cell Reports, 2015, 5, 946-953.	4.8	47
119	Developmental clock compromises human twin model created by embryo splitting. Human Reproduction, 2015, 30, dev252.	0.9	20
120	Human embryonic and induced pluripotent stem cells in clinical trials: TableÂ1. British Medical Bulletin, 2015, 116, ldv045.	6.9	87
121	A Thyroid Hormone Receptor/KLF9 Axis in Human Hepatocytes and Pluripotent Stem Cells. Stem Cells, 2015, 33, 416-428.	3.2	42
122	Lowered Humidity Produces Human Epidermal Equivalents with Enhanced Barrier Properties. Tissue Engineering - Part C: Methods, 2015, 21, 15-22.	2.1	26
123	Wharton's jelly mesenchymal stromal/stem cells derived under chemically defined animal product-free low oxygen conditions are rich in MSCA-1⁺ subpopulation. Regenerative Medicine, 2014, 9, 723-732.	1.7	14
124	Sendai Virus-Based Reprogramming of Mesenchymal Stromal/Stem Cells from Umbilical Cord Whartonâ€™s Jelly into Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2014, 1357, 33-44.	0.9	16
125	Cost-Effective Master Cell Bank Validation of Multiple Clinical-Grade Human Pluripotent Stem Cell Lines From a Single Donor. Stem Cells Translational Medicine, 2014, 3, 1116-1124.	3.3	20
126	sPLA2 and the epidermal barrier. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 416-421.	2.4	36

#	Article	IF	Citations
127	Isolation and Expansion of Mesenchymal Stromal/Stem Cells from Umbilical Cord Under Chemically Defined Conditions. Methods in Molecular Biology, 2014, 1283, 65-71.	0.9	14
128	3D InÂVitro Model of a Functional Epidermal Permeability Barrier from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Stem Cell Reports, 2014, 2, 675-689.	4.8	97
129	Strategy for the creation of clinical grade hESC line banks that HLAâ€match a target population. EMBO Molecular Medicine, 2013, 5, 10-17.	6.9	48
130	Industry update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2013, 8, 689-694.	1.7	0
131	Promises and challenges of the first clinical-grade induced pluripotent stem cell bank. Regenerative Medicine, 2013, 8, 101-102.	1.7	5
132	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2012, 7, 141-145.	1.7	1
133	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2012, 7, 269-273.	1.7	1
134	Stem cell based therapyâ€"where are we going?. Lancet, The, 2012, 379, 877-878.	13.7	23
135	Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy, 2012, 14, 122-128.	0.7	77
136	Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal productâ€"free environment. Nature Protocols, 2012, 7, 1366-1381.	12.0	70
137	Umbilical cord blood stem cells: clinical trials in non-hematological disorders. British Medical Bulletin, 2012, 102, 43-57.	6.9	42
138	Walking at speeds close to the preferred transition speed as an approach to obesity treatment. Srpski Arhiv Za Celokupno Lekarstvo, 2012, 140, 58-64.	0.2	7
139	GROÎ± regulates human embryonic stem cell self-renewal or adoption of a neuronal fate. Differentiation, 2011, 81, 222-232.	1.9	32
140	Human Embryonic Stem Cells Derived from Embryos at Different Stages of Development Share Similar Transcription Profiles. PLoS ONE, 2011, 6, e26570.	2.5	22
141	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2011, 6, 145-156.	1.7	0
142	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2011, 6, 543-549.	1.7	0
143	Conversion of Mechanical Force into TGF-Î²-Mediated Biochemical Signals. Current Biology, 2011, 21, 933-941.	3.9	316
144	Snail1 controls epithelialâ€"mesenchymal lineage commitment in focal adhesion kinaseâ€"null embryonic cells. Journal of Cell Biology, 2011, 195, 729-738.	5.2	51

#	Article	IF	Citations
145	Industry highlights: Stem cell and regenerative medicine. Regenerative Medicine, 2011, 6, 55-60.	1.7	4
146	Global update: England and Wales. Regenerative Medicine, 2011, 6, 144-147.	1.7	0
147	Stem cells in regenerative medicine: introduction. British Medical Bulletin, 2011, 98, 117-126.	6.9	91
148	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2010, 5, 695-700.	1.7	1
149	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2010, 5, 165-173.	1.7	0
150	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2010, 5, 323-330.	1.7	2
151	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2010, 5, 11-20.	1.7	0
152	Stem cell therapies for recessive dystrophic epidermolysis bullosa. British Journal of Dermatology, 2010, 163, 1149-1156.	1.5	21
153	Safety paradigm: genetic evaluation of therapeutic grade human embryonic stem cells. Journal of the Royal Society Interface, 2010, 7, S677-88.	3.4	30
154	Effect of Karyotype on Successful Human Embryonic Stem Cell Derivation. Stem Cells and Development, 2010, 19, 39-46.	2.1	29
155	Conference Scene: Challenges to commercialization. Regenerative Medicine, 2010, 5, 341-343.	1.7	0
156	Industry Update: Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2010, 5, 607-615.	1.7	4
157	Human embryonic stem cells as a model for embryotoxicity screening. Regenerative Medicine, 2009, 4, 449-459.	1.7	37
158	Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2009, 4, 11-25.	1.7	1
159	Derivation of Human Embryonic Stem Cell Lines From Biopsied Blastomeres on Human Feeders With Minimal Exposure to Xenomaterials. Stem Cells and Development, 2009, 18, 1343-1350.	2.1	59
160	Conference Scene: Venture capital and emerging regenerative medicine companies. Regenerative Medicine, 2009, 4, 375-376.	1.7	0
161	Industry Report. Regenerative Medicine, 2009, 4, 797-804.	1.7	0
162	FAK nuclear export signal sequences. FEBS Letters, 2008, 582, 2402-2406.	2.8	53

#	Article	IF	Citations
163	Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation. Molecular Cell, 2008, 29, 9-22.	9.7	421
164	Human Embryonic Stem Cell Lines Generated without Embryo Destruction. Cell Stem Cell, 2008, 2, 113-117.	11.1	217
165	PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility. Journal of Cell Biology, 2008, 180, 187-203.	5.2	196
166	Logistics of stem cell isolation, preparation and delivery for heart repair: concerns of clinicians, manufacturers, investors and public health. Regenerative Medicine, 2008, 3, 83-91.	1.7	7
167	Establishment of Cell Lines from Mouse Embryos with Early Embryonic Lethality. Cell Communication and Adhesion, 2008, 15, 379-383.	1.0	3
168	Isolation of Human Placental Fibroblasts. Current Protocols in Stem Cell Biology, 2008, 5, Unit 1C.6.	3.0	15
169	Latest developments in stem cell research and regenerative medicine. Regenerative Medicine, 2008, 3, 257-267.	1.7	1
170	Focal adhesion kinase mediates cell survival via NF-Î²B and ERK signaling pathways. American Journal of Physiology - Cell Physiology, 2007, 292, C1339-C1352.	4.6	69
171	Derivation of hESC from Intact Blastocysts. Current Protocols in Stem Cell Biology, 2007, 1, Unit 1A.2.	3.0	30
172	Focal Adhesion Kinase Controls pH-Dependent Epidermal Barrier Homeostasis by Regulating Actin-Directed Na+/H+ Exchanger 1 Plasma Membrane Localization. American Journal of Pathology, 2007, 170, 2055-2067.	3.8	24
173	Analyzing FAK and Pyk2 in Early Integrin Signaling Events. Current Protocols in Cell Biology, 2006, 30, Unit 14.7.	2.3	9
174	Culture of human embryonic stem cells and the extracellular matrix microenvironment. Regenerative Medicine, 2006, 1, 95-101.	1.7	28
175	Hair cycle and wound healing in mice with a keratinocyte-restricted deletion of FAK. Oncogene, 2006, 25, 1081-1089.	5.9	52
176	Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene, 2006, 25, 5969-5984.	5.9	143
177	Reduced Expression of Focal Adhesion Kinase Disrupts Insulin Action in Skeletal Muscle Cells. Endocrinology, 2006, 147, 3333-3343.	2.8	43
178	Integrin Î±4Î²1 Promotes Focal Adhesion Kinase-Independent Cell Motility via Î±4 Cytoplasmic Domain-Specific Activation of c-Src. Molecular and Cellular Biology, 2005, 25, 9700-9712.	2.3	77
179	FAK promotes organization of fibronectin matrix and fibrillar adhesions. Journal of Cell Science, 2004, 117, 177-187.	2.0	106
180	Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1692, 77-102.	4.1	380

#	Article	IF	Citations
181	Focal Adhesion Kinase Is Required for Blood Vessel Morphogenesis. Circulation Research, 2003, 92, 300-307.	4.5	111
182	FAK induces expression of Prx1 to promote tenascin-Câ€“dependent fibroblast migration. Journal of Cell Biology, 2003, 161, 393-402.	5.2	71
183	Differential regulation of cell motility and invasion by FAK. Journal of Cell Biology, 2003, 160, 753-767.	5.2	484
184	Trophoblast L-Selectin-Mediated Adhesion at the Maternal-Fetal Interface. Science, 2003, 299, 405-408.	12.6	437
185	v-Src SH3-enhanced Interaction with Focal Adhesion Kinase at Î²1 Integrin-containing Invadopodia Promotes Cell Invasion. Journal of Biological Chemistry, 2002, 277, 12487-12490.	3.4	102
186	Integrin signaling: it's where the action is. Current Opinion in Cell Biology, 2002, 14, 594-602.	5.4	157
187	Biological and Clinical Significance of Clonogenic Assays in Patients with Myelodysplastic Syndromes. Medical Oncology, 2002, 19, 249-260.	2.5	14
188	Plasma Membrane-Associated pY397FAK Is a Marker of Cytotrophoblast Invasion in Vivo and in Vitro. American Journal of Pathology, 2001, 159, 93-108.	3.8	86
189	Focal Adhesion Kinase and p130Cas Mediate Both Sarcomeric Organization and Activation of Genes Associated with Cardiac Myocyte Hypertrophy. Molecular Biology of the Cell, 2001, 12, 2290-2307.	2.1	85
190	FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell Biology, 2000, 2, 249-256.	10.3	1,108
191	Matrix Survival Signaling. Journal of Cell Biology, 2000, 149, 741-754.	5.2	354
192	Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. Journal of Cell Science, 1999, 112, 4067-4078.	2.0	138
193	Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO Journal, 1998, 17, 5933-5947.	7.8	298
194	Extracellular Matrix Survival Signals Transduced by Focal Adhesion Kinase Suppress p53-mediated Apoptosis. Journal of Cell Biology, 1998, 143, 547-560.	5.2	459
195	c-Src Activation Plays a Role in Endothelin-dependent Hypertrophy of the Cardiac Myocyte. Journal of Biological Chemistry, 1998, 273, 35185-35193.	3.4	62
196	Skin abnormality in aged fyn-/- fak+/- mice. Carcinogenesis, 1997, 18, 1473-1476.	2.8	13
197	Focal adhesion kinase: at the crossroads of signal transduction. Journal of Cell Science, 1997, 110, 401-407.	2.0	228
198	Focal adhesion kinase: at the crossroads of signal transduction. Journal of Cell Science, 1997, 110 (Pt) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.0	61

#	Article	IF	Citations
199	Impairment of Mobility in Endodermal Cells by FAK Deficiency. Experimental Cell Research, 1996, 222, 298-303.	2.6	73
200	p59fyn-p125FAK cooperation in development of CD4+CD8+ thymocytes. Blood, 1996, 87, 865-870.	1.4	24
201	p59fyn-p125FAK cooperation in development of CD4+CD8+ thymocytes. Blood, 1996, 87, 865-70.	1.4	8
202	Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature, 1995, 377, 539-544.	27.8	1,698
203	Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity, 1995, 3, 549-560.	14.3	454
204	Focal Adhesion Kinase Is Not Essential for in Vitro and in Vivo Differentiation of ES Cells. Biochemical and Biophysical Research Communications, 1995, 209, 300-309.	2.1	56
205	Integrin Stimulation Decreases Tyrosine Phosphorylation and Activity of Focal Adhesion Kinase in Thymocytes. Biochemical and Biophysical Research Communications, 1995, 215, 438-445.	2.1	11
206	Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene, 1995, 11, 1989-95.	5.9	160
207	Differential responses of p56lyn and p53lyn, products of alternatively spliced lyn mRNA, on stimulation of B-cell antigen receptor.. Molecular Biology of the Cell, 1991, 2, 979-987.	6.5	24
208	Industry updates from the field of stem cell research and regenerative medicine in May 2022. Regenerative Medicine, 0, , .	1.7	0